GlassScriptPhysician profile
Lisa J Go
NPI 1184683492
$4,652.58
in general payments reported to CMS, 2019-2025
30 companies · $1,161 in 2025
The $1,161 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $686 · 2020: $69.86 · 2021: $94.26 · 2022: $922 · 2023: $936 · 2024: $783 · 2025: $1,161.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,881.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,881.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $429.74 | 2022-2023 | Pemazyre, Monjuvi, Jakafi |
| Daiichi Sankyo INC. | $359.13 | 2022-2025 | Enhertu |
| Astrazeneca Pharmaceuticals LP | $330.50 | 2022-2024 | Imfinzi |
| Agios Pharmaceuticals, INC. | $253.94 | 2024 | Pyrukynd |
| Astellas Pharma US INC | $250.37 | 2024-2025 | Vyloy |
| Glaxosmithkline, LLC. | $238.01 | 2022-2023 | |
| Ipsen Biopharmaceuticals, INC | $223.75 | 2019-2024 | Onivyde |
| Seagen INC. | $214.05 | 2019-2022 | |
| Janssen Biotech, INC. | $180.24 | 2022-2023 | Tecvayli |
| Bayer Healthcare Pharmaceuticals INC. | $159.67 | 2022-2025 | |
| Gilead Sciences, INC. | $147.34 | 2025 | Trodelvy |
| E.R. Squibb & Sons, L.L.C. | $127.75 | 2019-2025 | |
| Jazz Pharmaceuticals INC. | $121.84 | 2023 | |
| Regeneron Pharmaceuticals, INC. | $119.58 | 2025 | Libtayo |
| Apellis Pharmaceuticals, INC. | $119.27 | 2024 | Empaveli |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $114.46 | 2019 | |
| Genentech USA, INC. | $113.31 | 2019 | |
| Eisai INC. | $112.58 | 2019 | |
| Genentech, INC. | $110.18 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $105.81 | 2025 | Iclusig |
| Pfizer INC. | $103.47 | 2025 | |
| Genmab U.S., INC. | $101.83 | 2024 | Epkinly |
| Geron Corporation | $101.32 | 2025 | Rytelo |
| Kite Pharma, INC. | $101.32 | 2022 | |
| Emd Serono, INC. | $101.32 | 2023 | Bavencio |
| Regeneron Healthcare Solutions, INC. | $94.26 | 2021 | |
| Rigel Pharmaceuticals, INC. | $69.86 | 2020 | |
| Janssen Scientific Affairs, LLC | $63.10 | 2025 | Rybrevant |
| Stemline Therapeutics INC. | $51.30 | 2023 | Orserdu |
| Beone Medicines USA, INC. | $33.28 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Go listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.